KDM1A and breast cancer: These findings suggest two translational opportunities: (i) FLI1 could be used as a pharmacodynamic biomarker of breast cancer metastastatic potential, capturing stromal and immune remodeling, and (ii) combining direct FLI1 inhibition and LSD1 blockade may yield stnergistic therapeutic effects.